A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC

计划入组 66 人 · 首次发布于 2025 年 11 月 24 日

A Study of DES-1357 in People With Deficient Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer (mCRC)

计划入组 88 人 · 首次发布于 2026 年 9 月 8 日

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

计划入组 839 人 · 首次发布于 2019 年 7 月 5 日

MSI-753

MSI-1566

MSI-2511

MSI ASIA PACIFIC

Australia

MSI Methylation Sciences Inc

Canada

H & H EXPORTS, LLC

United States

Nivolumab Plus Ipilimumab Demonstrates Superior PFS in MSI-H/dMMR Metastatic Colorectal Cancer

FDA Grants Fast Track Designation to Botensilimab Plus Balstilimab for Non-MSI-H/dMMR mCRC

Study Reveals Factors Influencing Immune Checkpoint Inhibitor Efficacy in Metastatic Colorectal Cancer